CPAMD8

Across TCGA pan-cancer cohorts, CPAMD8 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CPAMD8 data layer compared with 27 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CPAMD8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CPAMD8 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD are the cancer types where CPAMD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.887	0.499	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CPAMD8–LUAD (DFS)

Open the LUAD breakdown →